Morgan Stanley’s Charles River Laboratories CRL Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $182M | Sell |
800,487
-25,181
| -3% | -$4.48M | 0.01% | 1103 |
|
|
2026
Q1 | $142M | Buy |
825,668
+32,848
| +4% | +$6.09M | 0.01% | 1163 |
|
|
2025
Q4 | $158M | Sell |
792,820
-41,969
| -5% | -$7.61M | 0.01% | 1085 |
|
|
2025
Q3 | $131M | Buy |
834,789
+79,926
| +11% | +$12.7M | 0.01% | 1194 |
|
|
2025
Q2 | $115M | Buy |
754,863
+295,854
| +64% | +$39.5M | 0.01% | 1220 |
|
|
2025
Q1 | $69.1M | Sell |
459,009
-19,488
| -4% | -$3.27M | ﹤0.01% | 1526 |
|
|
2024
Q4 | $88.3M | Buy |
478,497
+10,299
| +2% | +$1.98M | 0.01% | 1349 |
|
|
2024
Q3 | $92.2M | Sell |
468,198
-13,576
| -3% | -$2.82M | 0.01% | 1308 |
|
|
2024
Q2 | $99.5M | Buy |
481,774
+46,715
| +11% | +$10.6M | 0.01% | 1182 |
|
|
2024
Q1 | $118M | Sell |
435,059
-37,051
| -8% | -$8.85M | 0.01% | 1078 |
|
|
2023
Q4 | $112M | Sell |
472,110
-53,183
| -10% | -$10.5M | 0.01% | 1083 |
|
|
2023
Q3 | $103M | Buy |
525,293
+12,342
| +2% | +$2.53M | 0.01% | 1039 |
|
|
2023
Q2 | $108M | Buy |
512,951
+58,539
| +13% | +$11.6M | 0.01% | 1040 |
|
|
2023
Q1 | $91.7M | Sell |
454,412
-20,019
| -4% | -$4.54M | 0.01% | 1104 |
|
|
2022
Q4 | $103M | Buy |
474,431
+193,250
| +69% | +$42.2M | 0.01% | 1013 |
|
|
2022
Q3 | $55.3M | Sell |
281,181
-50,606
| -15% | -$10.9M | 0.01% | 1251 |
|
|
2022
Q2 | $71M | Buy |
331,787
+138,733
| +72% | +$33.9M | 0.01% | 1135 |
|
|
2022
Q1 | $54.8M | Sell |
193,054
-5,994
| -3% | -$1.85M | 0.01% | 1244 |
|
|
2021
Q4 | $75M | Buy |
199,048
+11,556
| +6% | +$4.49M | 0.01% | 1073 |
|
|
2021
Q3 | $77.4M | Sell |
187,492
-51,373
| -22% | -$21.3M | 0.01% | 992 |
|
|
2021
Q2 | $88.4M | Buy |
238,865
+71,153
| +42% | +$23.8M | 0.01% | 931 |
|
|
2021
Q1 | $48.6M | Sell |
167,712
-18,698
| -10% | -$5.2M | 0.01% | 1196 |
|
|
2020
Q4 | $46.6M | Buy |
186,410
+104,440
| +127% | +$24.9M | 0.01% | 1148 |
|
|
2020
Q3 | $18.6M | Buy |
81,970
+15,891
| +24% | +$3.3M | ﹤0.01% | 1539 |
|
|
2020
Q2 | $11.5M | Sell |
66,079
-33,782
| -34% | -$5.39M | ﹤0.01% | 1848 |
|
|
2020
Q1 | $12.6M | Sell |
99,861
-6,845
| -6% | -$1.03M | ﹤0.01% | 1600 |
|
|
2019
Q4 | $16.3M | Sell |
106,706
-82,406
| -44% | -$11.4M | ﹤0.01% | 1844 |
|
|
2019
Q3 | $25M | Buy |
189,112
+6,371
| +3% | +$854K | 0.01% | 1317 |
|
|
2019
Q2 | $25.9M | Buy |
182,741
+39,716
| +28% | +$5.39M | 0.01% | 1294 |
|
|
2019
Q1 | $20.8M | Sell |
143,025
-4,349
| -3% | -$571K | 0.01% | 1409 |
|
|
2018
Q4 | $16.7M | Sell |
147,374
-40,464
| -22% | -$5.07M | 0.01% | 1628 |
|
|
2018
Q3 | $25.3M | Buy |
187,838
+126,456
| +206% | +$15.6M | 0.01% | 1475 |
|
|
2018
Q2 | $6.89M | Sell |
61,382
-60,138
| -49% | -$6.5M | ﹤0.01% | 2783 |
|
|
2018
Q1 | $13M | Buy |
121,520
+26,816
| +28% | +$2.89M | ﹤0.01% | 2089 |
|
|
2017
Q4 | $10.4M | Sell |
94,704
-804,878
| -89% | -$87.6M | ﹤0.01% | 2356 |
|
|
2017
Q3 | $97.2M | Sell |
899,582
-55,066
| -6% | -$5.66M | 0.03% | 571 |
|
|
2017
Q2 | $96.6M | Buy |
954,648
+336,887
| +55% | +$31M | 0.03% | 570 |
|
|
2017
Q1 | $55.6M | Buy |
617,761
+412,894
| +202% | +$35.1M | 0.02% | 849 |
|
|
2016
Q4 | $15.6M | Buy |
204,867
+130,047
| +174% | +$9.88M | 0.01% | 1778 |
|
|
2016
Q3 | $6.24M | Sell |
74,820
-67,619
| -47% | -$5.67M | ﹤0.01% | 2457 |
|
|
2016
Q2 | $11.7M | Sell |
142,439
-134,058
| -48% | -$11M | ﹤0.01% | 1850 |
|
|
2016
Q1 | $21M | Sell |
276,497
-16,751
| -6% | -$1.24M | 0.01% | 1273 |
|
|
2015
Q4 | $23.6M | Buy |
293,248
+55,393
| +23% | +$4M | 0.01% | 1275 |
|
|
2015
Q3 | $15.1M | Buy |
237,855
+113,320
| +91% | +$8.14M | 0.01% | 1613 |
|
|
2015
Q2 | $8.76M | Sell |
124,535
-184,365
| -60% | -$13.6M | ﹤0.01% | 2232 |
|
|
2015
Q1 | $24.5M | Sell |
308,900
-17,014
| -5% | -$1.26M | 0.01% | 1296 |
|
|
2014
Q4 | $20.7M | Buy |
325,914
+15,049
| +5% | +$943K | 0.01% | 1464 |
|
|
2014
Q3 | $18.6M | Buy |
310,865
+47,014
| +18% | +$2.69M | 0.01% | 1499 |
|
|
2014
Q2 | $14.1M | Buy |
263,851
+124,844
| +90% | +$6.85M | 0.01% | 1726 |
|
|
2014
Q1 | $8.39M | Sell |
139,007
-98,011
| -41% | -$5.71M | ﹤0.01% | 2098 |
|
|
2013
Q4 | $12.6M | Buy |
237,018
+81,891
| +53% | +$4.11M | 0.01% | 1751 |
|
|
2013
Q3 | $7.18M | Buy |
155,127
+11,421
| +8% | +$524K | ﹤0.01% | 2081 |
|
|
2013
Q2 | $5.9M | Buy |
+143,706
| New | +$6.16M | ﹤0.01% | 2167 |
|
Other funds holding CRL
AI
Morgan Stanley's CRL Position: Q2 2026 in Review
Morgan Stanley reduced its Charles River Laboratories (CRL) stake by 3% in Q2 2026, selling an estimated $4.48M and leaving 800,487 shares worth $182M. The position accounts for 0.01% of the portfolio, ranked #1103.
Morgan Stanley first reported a position in CRL in Q2 2013 and has held it in 53 quarters since. 568 funds tracked by Wall St. Rank hold CRL as of Q2 2026.
- Morgan Stanley held 800,487 shares of Charles River Laboratories worth $182M as of Q2 2026.
- Morgan Stanley sold 25,181 Charles River Laboratories shares in Q2 2026, an estimated $4.48M.
- Charles River Laboratories made up 0.01% of Morgan Stanley's portfolio in Q2 2026, its #1103 holding.
- Morgan Stanley first reported a position in Charles River Laboratories in Q2 2013 and has held it in 53 quarters since.
- 568 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2026.
Based on Morgan Stanley's 13F filing for Q2 2026, filed 13 Aug 2026.